Japan Human Insulin Market Insights Forecasts to 2033

• The Human Insulin Market Size was valued at USD 780.23 Million in 2023.
• The Market Size is Growing at a CAGR of 6.39% from 2023 to 2033
• The Japan Human Insulin Market Size is Expected to Reach USD 1450.13 Million by 2033

The Japan Human Insulin Market Size is Anticipated to Reach USD 1450.13 Million by 2033, growing at a CAGR of 6.39% from 2023 to 2033.

Market Overview

Insulin made in laboratories that closely resembles the insulin that the body of humans produces is referred to as human insulin. The synthesized human insulin is purer than the extracted animal insulin, which lowers the production of antibodies. Some researchers are introducing human insulin into plants to discover a novel method of generating insulin in safflower, known as biopharming. The cost of producing insulin should go down due to this new production technique. When using human insulin, adverse consequences including fatigue and weight gain happen, but not when using animal insulin. Human insulin is utilized for treating type 1 diabetes, a medical disorder in which the human body is unable to generate insulin and cannot control blood sugar levels, as well as type 2 diabetes, a circumstance in which the body fails to generate or utilize insulin generally and results in excessive blood sugar levels that are uncontrollable even with oral medication.

Report Coverage

This research report categorizes the market for the Japan human insulin market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan human insulin market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan human insulin market.

Driving Factors

Diabetes has been rising quickly in Japan recently. IDF forecasts for 2021 state that 11 million adults in Japan suffer from diabetes. The high incidence of diabetes is linked to substantial financial burdens and can be explained by longer lifespans and lifestyle modifications According to this information, Japan is experiencing a rise in the need for human insulin. Japan's growing diabetes care infrastructure contributes to the market's rise. The implementation of specialist diabetic clinics, all-inclusive care facilities, and management initiatives enhances patient accessibility to cutting-edge insulin therapies.

Restraining Factors

In certain regions of Japan, inadequate understanding of diabetes and insulin therapy may lead to inadequate treatment and inefficient control of blood sugar levels.

Market Segmentation

The Japan human insulin market share is classified into product type and distribution channel.

• The drugs segment is expected to hold the largest market share through the forecast period.   

The Japan human insulin market is segmented by product type into drugs and delivery devices. Among these, the drugs segment is expected to hold the largest market share through the forecast period. In general, human insulin medications are more readily available and reasonably priced when compared to more recent, proprietary insulin substitutes. The widespread usage of these medications has been facilitated by their price and ease of access, especially in environments with low resources.

• The hospital pharmacies segment is expected to dominate the Japan human insulin market during the forecast period.       

Based on the distribution channel, the Japan human insulin market is divided into retail pharmacies, hospital pharmacies, online retail stores, and others. Among these, the hospital pharmacies segment is expected to dominate the Japan human insulin market during the forecast period. Many important aspects of the Japanese medical system and controlling diabetes are fundamental to this dominance. Due to their all-encompassing strategy for diabetes treatment, hospitals are essential to managing and keeping track of insulin therapies.    

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan human insulin market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Eli Lilly Japan K.K.
• Sanofi K.K.
• Novo Nordisk Pharma Ltd.
• Nippon Boehringer Ingelheim Co., Ltd.
• Novartis Pharma K.K.
• Janssen Pharmaceuticals K.K.
• Sun Pharma Japan Limited
• Otsuka Pharmaceutical Co., Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In November 2023, to keep up with rising demand, Novo Nordisk (NOVOb.CO), opened a new tab, and announced a $2.3 Million investment to expand the manufacture of its massively popular diabetic and weight-loss medications at a location in Chartres, Japan.

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Japan Human Insulin Market based on the below-mentioned segments:

Japan Human Insulin Market, By Product Type

• Drugs
• Delivery Devices

Japan Human Insulin Market, By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Retail Stores
• Others